Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells

被引:134
作者
Ishimura, N [1 ]
Isomoto, H [1 ]
Bronk, SF [1 ]
Gores, GJ [1 ]
机构
[1] Mayo Clin & Mayo Fdn, Coll Med, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA
来源
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY | 2006年 / 290卷 / 01期
关键词
cholangiocyte; tumor necrosis factor-related apoptosis-inducing ligand; nuclear factor-kappa B; malignant phenotype;
D O I
10.1152/ajpgi.00242.2005
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Tumor necrosis factorrelated apoptosis-inducing ligand ( TRAIL) is a promising agent for cancer therapy; however, many cholangiocarcinoma cells are resistant to TRAIL-mediated apoptosis. Resistance to apoptosis may unmask TRAIL signaling cascades favoring tumor biology. Thus our aim was to examine whether TRAIL is expressed by human cholangiocarcinomas, and if so, to determine whether it promotes a malignant phenotype. To address this objective, TRAIL expression in human liver specimens was evaluated by immunohistochemistry. The effect of TRAIL on tumor cell migration, invasion, and proliferation was examined in three human cholangiocarcinoma cell lines. TRAIL expression was upregulated by cholangiocytes in preneoplastic disease, primary sclerosing cholangitis, and human cholangiocarcinoma specimens. TRAIL promoted tumor cell migration and invasion but did not induce cell proliferation. TRAIL-mediated cell migration and invasion was NF-kappa B dependent. These data demonstrate that TRAIL promotes cell migration and invasion via a NF-kappa B-dependent pathway in human cholangiocarcinoma cell lines, an observation that has a potential negative implication for TRAIL in cancer therapy.
引用
收藏
页码:G129 / G136
页数:8
相关论文
共 52 条
[31]   NF-κB functions as a tumour promoter in inflammation-associated cancer [J].
Pikarsky, E ;
Porat, RM ;
Stein, I ;
Abramovitch, R ;
Amit, S ;
Kasem, S ;
Gutkovich-Pyest, E ;
Urieli-Shoval, S ;
Galun, E ;
Ben-Neriah, Y .
NATURE, 2004, 431 (7007) :461-466
[32]   Cholangiocarcinomas express Fas ligand and disable the Fas receptor [J].
Que, FG ;
Phan, VA ;
Phan, VH ;
Celli, A ;
Batts, K ;
LaRusso, NF ;
Gores, GJ .
HEPATOLOGY, 1999, 30 (06) :1398-1404
[33]   The pathobiology of biliary epithelia [J].
Roberts, SK ;
Ludwig, J ;
LaRusso, NF .
GASTROENTEROLOGY, 1997, 112 (01) :269-279
[34]   The bile acid taurochenodexoycholate activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade [J].
Rust, C ;
Karnitz, LM ;
Paya, CV ;
Moscat, J ;
Simari, RD ;
Gores, GJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (26) :20210-20216
[35]   TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways [J].
Secchiero, P ;
Gonelli, A ;
Carnevale, E ;
Milani, D ;
Pandolfi, A ;
Zella, D ;
Zauli, G .
CIRCULATION, 2003, 107 (17) :2250-2256
[36]   Evidence for a proangiogenic activity of TNF-related apoptosis-inducing ligand [J].
Secchiero, P ;
Gonelli, A ;
Carnevale, E ;
Corallini, F ;
Rizzardi, C ;
Zacchigna, S ;
Melato, M ;
Zauli, G .
NEOPLASIA, 2004, 6 (04) :364-373
[37]   The epidemiology of cholangiocarcinoma [J].
Shaib, Y ;
El-Serag, HB .
SEMINARS IN LIVER DISEASE, 2004, 24 (02) :115-125
[38]   Cholangiocarcinoma: Molecular targeting strategies for chemoprevention and therapy [J].
Sirica, AE .
HEPATOLOGY, 2005, 41 (01) :5-15
[39]  
Spierings DCJ, 2003, CLIN CANCER RES, V9, P3397
[40]   Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis [J].
Taimr, P ;
Higuchi, H ;
Kocova, E ;
Rippe, RA ;
Friedman, S ;
Gores, GJ .
HEPATOLOGY, 2003, 37 (01) :87-95